Literature DB >> 11014575

Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.

B Davidson1, A Berner, J M Nesland, B Risberg, G B Kristensen, C G Tropé, M Bryne.   

Abstract

The object of this study was the investigation of carbohydrate antigen expression in malignant epithelial cells and benign mesothelial cells in serous effusions from patients diagnosed with epithelial ovarian carcinomas. In addition, to compare antigen expression in carcinoma cells in effusions with those of corresponding primary tumors and metastatic lesions. Sections from 63 malignant effusions from ovarian carcinoma patients and 15 reactive effusions were immunohistochemically stained, using 5 monoclonal antibodies for Lewis(y), Sialyl Lewis(x), Tn, and Sialyl Tn antigens. Tissue sections (n = 97) from corresponding primary ovarian carcinomas and metastatic lesions, as well as from 12 malignant mesotheliomas, were additionally stained using the above panel. Staining for the 4 antigens was seen in carcinoma cells in serous effusions in the majority of cases (range = 71% to 85%). In contrast, immunoreactivity was detected in mesothelial cells in only 6% to 23% of the specimens studied (P < .001 for all 5 markers). With the exception of B3 antibody against Lewis(y) antigen, malignant mesotheliomas stained negative, infrequently showing focal immunoreactivity. An up-regulation of Tn and Sialyl Tn expression was detected in carcinoma cells in effusions when compared with both primary tumors (P < .003 and P < .007, respectively) and metastatic lesions (P < .034 and .041, respectively). Cancer-associated carbohydrate antigens can thus be used as an adjunct in the differentiation between malignant epithelial and reactive mesothelial cells. Ovarian carcinoma cells in effusions show up-regulation of Tn and Sialyl Tn, possibly representing a transient phenotypic alteration facilitating metastasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014575     DOI: 10.1053/hupa.2000.9776

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  18 in total

1.  Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications.

Authors:  H S Berner; B Davidson; A Berner; B Risberg; G B Kristensen; C G Trope; G Van de Putte; J M Nesland
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.

Authors:  Sara Ricardo; Lara Marcos-Silva; Daniela Pereira; Rita Pinto; Raquel Almeida; Ola Söderberg; Ulla Mandel; Henrik Clausen; Ana Felix; Nuno Lunet; Leonor David
Journal:  Mol Oncol       Date:  2014-10-22       Impact factor: 6.603

3.  EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.

Authors:  Ben Davidson; Iris Goldberg; Aasmund Berner; Gunnar B Kristensen; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

Review 4.  Carbohydrate recognition by boronolectins, small molecules, and lectins.

Authors:  Shan Jin; Yunfeng Cheng; Suazette Reid; Minyong Li; Binghe Wang
Journal:  Med Res Rev       Date:  2010-03       Impact factor: 12.944

5.  The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.

Authors:  Ben Davidson; Iris Goldberg; Liora Tell; Sophya Vigdorchik; Mark Baekelandt; Aasmund Berner; Gunnar B Kristensen; Reuven Reich; Juri Kopolovic
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

6.  Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma.

Authors:  Vered Givant-Horwitz; Ben Davidson; Gregg van de Putte; Hiep Phuc Dong; Iris Goldberg; Sivan Amir; Gunnar B Kristensen; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

7.  Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.

Authors:  Ben Davidson; Vered Givant-Horwitz; Philip Lazarovici; Björn Risberg; Jahn M Nesland; Claes G Trope; Erik Schaefer; Reuven Reich
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours.

Authors:  José Alexandre Ferreira; Paula A Videira; Luís Lima; Sofia Pereira; Mariana Silva; Mylène Carrascal; Paulo F Severino; Elisabete Fernandes; Andreia Almeida; Céu Costa; Rui Vitorino; Teresina Amaro; Maria J Oliveira; Celso A Reis; Fabio Dall'Olio; Francisco Amado; Lúcio Lara Santos
Journal:  Mol Oncol       Date:  2013-03-21       Impact factor: 6.603

9.  Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors.

Authors:  Sara Ricardo; Lara Marcos-Silva; Cristina Valente; Ricardo Coelho; Rosa Gomes; Leonor David
Journal:  Virchows Arch       Date:  2016-03-22       Impact factor: 4.064

10.  Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients.

Authors:  Marci E Schaner; Ben Davidson; Martina Skrede; Reuven Reich; Vivi Ann Flørenes; Björn Risberg; Aasmund Berner; Iris Goldberg; Vered Givant-Horwitz; Claes G Tropè; Gunnar B Kristensen; Jahn M Nesland; Anne-Lise Børresen-Dale
Journal:  Mol Cancer       Date:  2005-07-21       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.